Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A

Biochemical and Biophysical Research Communications

Volumn 381, Issue 1, 2009, Pages 50-53

  Masuyer, Geoffrey ^a   Thiyagarajan, Nethaji ^a   James, Peter L ^b   Marks, Philip M H ^b   Chaddock, John A ^b   Acharya, K Ravi ^a  

^a University of Bath   (United Kingdom)

^b SYNTAXIN LTD   (United Kingdom)

Author keywords

Botulinum neurotoxin; Crystal structure; Fusion; Protein engineering; Therapeutics

Indexed keywords

BOTULINUM TOXIN A; PROTEINASE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ARTICLE; CRYSTAL STRUCTURE; DRUG STRUCTURE; ENZYME ACTIVE SITE; LIGHT CHAIN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN ENGINEERING; X RAY DIFFRACTION;

BOTULINUM TOXIN TYPE A; CATALYSIS; CHOLINERGIC AGENTS; CRYSTALLOGRAPHY, X-RAY; ENDOPEPTIDASES; PROTEIN ENGINEERING; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25;

CLOSTRIDIUM BOTULINUM;

EID: 61649127494     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.02.003     Document Type: Article

References (20)

1. Barnes M.P. Introduction to the clinical use of Botulinum neurotoxins. In: Foster K.A., Hambleton P., and Shone C.C. (Eds). Treatments from toxins-the therapeutic potential of Clostridial neurotoxins (2007), CRC press, Boca Raton, Florida 139-162
2. Moore A.P. Expanding clinical uses of Botulinum neurotoxins. In: Foster K.A., Hambleton P., and Shone C.C. (Eds). Treatments from toxins-the therapeutic potential of Clostridial neurotoxins (2007), CRC press, Boca Raton, Florida 163-194
3. Chaddock J.A., Herbert M.H., Ling R.J., Alexander F.C.G., Fooks S.J., Revell D.F., Quinn C.P., Shone C.C., and Foster K.A. Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A. Protein Expr. Purif. 25 (2002) 219-228
4. Shone C.C., Hambleton P., and Melling J. Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity. Eur. J. Biochem. 151 (1985) 75-82
5. Chaddock J.A., Purkiss J.R., Alexander F.C.G., Doward S., Fooks S.J., Friis L.M., Hall Y.H.J., Kirby E.R., Leeds N., Moulsdale H.J., Dickenson A., Green G.M., Rahman W., Suzuki R., Duggan M.J., Quinn C.P., Shone C.C., and Foster K.A. Retargeted Clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain. Mov. Disord. 19 (2004) S42-S47
6. Chaddock J.A., Purkiss J.R., Friis L.M., Broadbridge J.D., Duggan M.J., Fooks S.J., Shone C.C., Quinn C.P., and Foster K.A. Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A. Infect. Immun. 68 (2000) 2587-2593
7. Chaddock J.A., Purkiss J.R., Duggan M.J., Quinn C.P., Shone C.C., and Foster K.A. A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors 18 (2000) 147-155
8. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
9. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography, Acta Cryst. D50 (1994) 760-763.
10. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., Read R.J., Rice L.M., Simonson T., and Warren G.L. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Cryst. D54 (1998) 905-921
11. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Cryst. D 60 (2004) 2126-2132
12. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 26 (1993) 283-291
13. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., Murray L.W., Arendall W.B., Snoeyink J., Richardson J.S., and Richardson D.C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35 (2007) W375-W383
14. Brunger A.T., Breidenbach M.A., Jin R., Fischer A., Santos J.S., and Montal M. Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog. 3 (2007) 1191-1194
15. Galloux M., Vitrac H., Montagner C., Raffestin S., Popoff M.R., Chenal A., Forge V., and Gillet D. Membrane interaction of botulinum neurotoxin A translocation (T) doma. The belt region is a regulatory loop for membrane interaction. J. Biol. Chem. 283 (2008) 27668-27676
16. Kurazono H., Mochida S., Binz T., Eisel U., Quanz M., Grebenstein O., Wernars K., Poulain B., Tauc L., and Niemann H. Minimal essential domains specifying toxicity of the light chains of tetanus toxin and botulinum neurotoxin type A. J. Biol. Chem. 267 (1992) 14721-14729
17. Koriazova L.K., and Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat. Struct. Biol. 10 (2003) 13-18
18. Chaddock J.A., and Marks P.M.H. Clostridial neurotoxins: structure-function led design of new therapeutics. Cell. Mol. Life Sci. 63 (2006) 540-551
19. Foster K.A. A new wrinkle on pain relief: re-engineering Clostridial neurotoxins for analgesics. Drug Discov. Today 10 (2005) 563-569
20. Smith L.A., and Rusnak J.M. Botulinum neurotoxin vaccines: past, present, and future. Crit. Rev. Immunol. 27 (2007) 303-318